DanCann Pharma Valuation
Is DAN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of DAN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate DAN's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate DAN's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for DAN?
Key metric: As DAN is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is DAN's PS Ratio? | |
|---|---|
| PS Ratio | 1x |
| Sales | DKK 8.22m |
| Market Cap | DKK 8.63m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.1x |
| Enterprise Value/EBITDA | -0.2x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does DAN's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 5.3x | ||
VP2 Valeo Pharma | 0.01x | 20.9% | €493.4k |
B8FK Biofrontera | 0.8x | n/a | €16.4m |
SBX SynBiotic | 7.2x | 39.7% | €27.9m |
0RX Redx Pharma | 13.3x | -37.6% | €65.0m |
DAN DanCann Pharma | 1x | n/a | €8.6m |
Price-To-Sales vs Peers: DAN is good value based on its Price-To-Sales Ratio (1x) compared to the peer average (5.3x).
Price to Sales Ratio vs Industry
How does DAN's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?
Price-To-Sales vs Industry: DAN is good value based on its Price-To-Sales Ratio (1x) compared to the European Pharmaceuticals industry average (3.1x).
Price to Sales Ratio vs Fair Ratio
What is DAN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate DAN's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Regeneron Pharmaceuticals
US$80.0b
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
RGO
US$705.00
7D
-7.1%
1Y
-3.8%
Amneal Pharmaceuticals
US$2.6b
Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.
2DT
US$7.60
7D
-6.2%
1Y
90.0%
Merck
US$246.5b
Operates as a healthcare company worldwide.
6MK
US$93.40
7D
0.3%
1Y
-0.4%